eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
2/2022
vol. 24
 
Share:
Send email
Share:
Varia

Recommendations of the Polish Society of Gynaecologists and Obstetricians, Polish Paediatric Society, Polish Society of Family Medicine, Polish Society of Vaccinology, Polish Society of Oncological Gynaecology and Polish Society for Colposcopy and Cervical Pathophysiology on prophylactic vaccinations against infections with human papillomaviruses in Poland

Andrzej Nowakowski
1, 2
,
Robert Jach
3
,
Leszek Szenborn
4
,
Mariusz Bidziński
5, 6
,
Teresa Jackowska
7
,
Jan Kotarski
8
,
Agnieszka Mastalerz-Migas
9
,
Aneta Nitsch-Osuch
10
,
Jarosław Pinkas
11
,
Włodzimierz Sawicki
12
,
Piotr Sieroszewski
13
,
Maciej Stukan
14, 15
,
Jacek Wysocki
16

1.
Cervical Cancer Prevention Clinic, Central Coordinating Centre for Cervical Cancer Screening Program, Department of Cancer Prevention, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
2.
Obstetrics and Gynaecology Ward, District Specialist Hospital, Siedlce, Poland
3.
Department of Endocrine Gynaecology, Collegium Medicum of the Jagiellonian University, Cracow, Poland; President of the Polish Society for Colposcopy and Cervical Pathophysiology, Vice President of the Polish Society of Gynaecologists and Obstetricians, Chairman of the Cervical Pathology, Colposcopy and Cytology Section of the Polish Society of Gynaecologists and Obstetricians, Member of the Board of the Polish Society of Oncological Gynaecology (PTGO) and Chairman of the Section for the prevention and treatment of cervical cancer at PTGO
4.
Clinical Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland; Polish Vaccinology Society
5.
Department of Oncological Gynaecology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; National Consultant Oncological Gynaecology
6.
Faculty of Medical Sciences and Health Sciences, Kazimierz Pulaski University of Technology and Humanities, Radom, Poland
7.
Department of Paediatrics, Centre of Postgraduate Medical Education, Warsaw, Poland; National Consultant in the field of Paediatrics, Polish Paediatric Society
8.
Medical University in Lublin, Lublin, Poland; Polish Society of Oncological Gynaecology
9.
Chair and Department of Family Medicine, Wroclaw Medical University, Wroclaw, Poland; National Consultant in Family Medicine
10.
Department of Social Medicine and Public Health, Warsaw Medical University, Warsaw, Poland; Polish Society of Family Medicine
11.
School of Public Health, Medical Centre of Postgraduate Education, Warsaw, Poland; National Consultant in Public Health
12.
Chair and Department of Obstetrics, Women’s Diseases and Oncological Gynaecology, Faculty of Medicine, Medical University of Warsaw, Warsaw, Poland; President of the Polish Society of Oncological Gynaecology
13.
First Department of Gynaecology and Obstetrics, Medical University of Lodz, Lodz, Poland; President Polish Society of Gynaecologists and Obstetricians
14.
Department of Gynaecological Oncology, Pomeranian Hospitals, Gdynia, Poland; Vice President of the Polish Society for Colposcopy and Cervical Pathophysiology
15.
Division of Oncological Propaedeutics, Medical University of Gdansk, Gdansk, Poland
16.
Observation and Infectious Diseases Department of the Specialist Mother and Child Healthcare Group in Poznan, Chair and Department of Health Prophylaxis, Medical University of Poznan, Poznan, Poland; Polish Society of Vaccinology
Family Medicine & Primary Care Review 2022; 24(2): 177–184
DOI: https://doi.org/10.5114/fmpcr.2022.116085
Online publish date: 2022/06/30
Article file
- 15 FM&PCR 2 22 - V - Nowakowski - Recommendations.pdf  [0.45 MB]
Get citation
 
PlumX metrics:
 
1. Global burden of HPV and HPV-related diseases [cited 20.10.2021]. Available from URL: https://hpvcentre.net/.
2. Co wiadomo o populacyjnych efektach szczepie przeciwko HPV? [cited 20.10.2021]. Available from URL: https://www.mp.pl/szczepienia/artykuly/przegladowe/186457,co-wiadomo-o-populacyjnych-efektach-szczepien-przeciwko-hpv (in Polish).
3. Martel C de, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 2017; 141(4): 664–670, doi: 10.1002/ijc.30716.
4. Sanjose S de, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11(11): 1048–1056, doi: 10.1016/S1470-2045(10)70230-8.
5. Nowakowski A, Souza SC de, Jach R, et al. HPV-type distribution and reproducibility of histological diagnosis in cervical neoplasia in Poland. Pathol Oncol Res 2015; 21(3): 703–711, doi: 10.1007/s12253-014-9877-4.
6. Cancers attributable to infections [cited 20.10.2021]. Available from URL: https://gco.iarc.fr/causes/infections/tools-pie?mode=2&sex=0&population=who&continent=0&country=0&population_group=0&cancer=0&key=attr_cases&lock_scale=0&pie_mode=1&nb_results=5.
7. World Health Organization. Weekly Epidemiological Record 2017. 2017; 92(19): 241–268.
8. Stanley M. HPV vaccines: alternative dosage schedules. Expert Rev Vaccines 2019; 18(12): 1309–1316, doi: 10.1080/14760584.2019. 1704261.
9. Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019; 394(10197): 497–509, doi: 10.1016/S0140-6736(19)30298-3.
10. Gidengil C, Goetz MB, Newberry S, et al. Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. Vaccine 2021; 39(28): 3696–3716, doi: 10.1016/j.vaccine.2021.03.079.
11. Andrews N, Stowe J, Miller E. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. Vaccine 2017; 35(13): 1729–1732, doi: 10.1016/j.vaccine.2017.01.076.
12. Hviid A, Thorsen NM, Valentiner-Branth P, et al. Association between quadrivalent human papillomavirus vaccination and selected syndromes with autonomic dysfunction in Danish females: population based, self-controlled, case series analysis. BMJ 2020; 370: m2930, doi: 10.1136/bmj.m2930.
13. Barboi A, Gibbons CH, Axelrod F, et al. Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society. Clin Auton Res 2020; 30(1): 13–18, doi: 10.1007/s10286-019-00608-w.
14. Gřtzsche PC, Jřrgensen KJ. EMA’s mishandling of an investigation into suspected serious neurological harms of HPV vaccines. BMJ Evid Based Med 2022; 27(1): 7–10, doi: 10.1136/bmjebm-2020-111470.
15. Tatang C, Arredondo Bisonó T, Bergamasco A, et al. Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System. Drugs Real World Outcomes 2022; 9(1): 79–90, doi: 10.1007/s40801-021-00271-6.
16. Bonaldo G, Vaccheri A, D’Annibali O, et al. Safety profile of human papilloma virus vaccines: an analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017. Br J Clin Pharmacol 2019; 85(3): 634–643, doi: 10.1111/bcp.13841.
17. Vichnin M, Bonanni P, Klein NP, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J 2015; 34(9): 983–991, doi: 10.1097/INF.0000000000000793.
18. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372(8): 711–723, doi: 10.1056/NEJMoa1405044.
19. Goss MA, Lievano F, Buchanan KM, et al. Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine 2015; 33(29): 3422–3428, doi: 10.1016/j.vaccine.2015.04.014.
20. Scheller NM, Pasternak B, Mřlgaard-Nielsen D, et al. Quadrivalent HPV Vaccination and the Risk of Adverse Pregnancy Outcomes.
21. N Engl J Med 2017; 376(13): 1223–1233, doi: 10.1056/NEJMoa1612296.
22. Schwarz TF, Huang LM, Lin TY, et al. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J 2014; 33(12): 1255–1261, doi: 10.1097/INF.0000000000000460.
23. Kjaer SK, Sigurdsson K, Iversen OE, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) 2009; 2(10): 868–878, doi: 10.1158/1940-6207.CAPR-09-0031.
24. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial [published correction appears in Lancet Oncol 2012; 13(1): e1]. Lancet Oncol 2012; 13(1): 89–99, doi: 10.1016/S1470-2045(11)70286-8.
25. Hildesheim A, Wacholder S, Catteau G, et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014; 32(39): 5087–5097, doi: 10.1016/j.vaccine.2014.06.038.
26. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males [published correction appears in N Engl J Med 2011; 364(15): 1481]. N Engl J Med 2011; 364(5): 401–411, doi: 10.1056/NEJMoa0909537.
27. Olsson SE, Restrepo JA, Reina JC, et al. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res 2020; 10: 100203, doi: 10.1016/j.pvr.2020.100203.
28. Kjaer SK, Nygĺrd M, Sundström K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine 2020; 23: 100401, doi: 10.1016/j.eclinm.2020.100401.
29. Lehtinen M, Apter D, Eriksson T, et al. Effectiveness of the AS04-adjuvanted HPV-16/18 vaccine in reducing oropharyngeal HPV infections in young females – results from a community-randomized trial. Int J Cancer 2020; 147(1): 170–174, doi: 10.1002/ijc.32791.
30. Brisson M, Bénard É, Drolet M, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health 2016; 1(1): e8–e17, doi: 10.1016/S2468-2667(16)30001-9.
31. Falcaro M, Castańon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 2021; 398(10316): 2084–2092, doi: 10.1016/S0140-6736(21)02178-4.
32. Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med 2020; 383(14): 1340–1348, doi: 10.1056/NEJMoa1917338.
33. Kjaer SK, Dehlendorff C, Belmonte F, et al. Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J Natl Cancer Inst 2021; 113(10): 1329–1335, doi: 10.1093/jnci/djab080.
34. Muńoz-Quiles C, López-Lacort M, Díez-Domingo J, et al. Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009–2017. Vaccine 2022; 40(2): 316–324, doi: 10.1016/j.vaccine.2021.11.062.
35. Yuill S, Egger S, Smith M, et al. Has Human Papillomavirus (HPV) Vaccination Prevented Adverse Pregnancy Outcomes? Population-Level Analysis After 8 Years of a National HPV Vaccination Program in Australia. J Infect Dis 2020; 222(3): 499–508, doi: 10.1093/infdis/jiaa106.
36. Dehlendorff C, Baandrup L, Kjaer SK. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers. J Natl Cancer Inst 2021; 113(7): 869–874, doi: 10.1093/jnci/djaa209.
37. Chaturvedi AK, Graubard BI, Broutian T, et al. Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin Oncol 2018; 36(3): 262–267, doi: 10.1200/JCO.2017.75.0141.
38. Denny LA, Franceschi S, Sanjosé S de, et al. Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine 2012; 30(Suppl. 5): F168–F174, doi: 10.1016/j.vaccine.2012.06.045.
39. Tanweer MS, Aljurf M, Savani BN, et al. Lower Genital Tract Precancer and Cancer in Hematopoietic Cell Transplant Survivors and the Role of HPV: A Systematic Review and Future Perspectives. Clin Hematol Int 2019; 1(3): 142–153, doi: 10.2991/chi.d.190519.001.
40. Gómez de la Rosa AG, Quesada López-Fe A, Vilar Chesa M, et al. Efficacy of Human Papillomavirus Vaccination 4 Years After Conization for High-Grade Cervical Neoplasia. J Low Genit Tract Dis 2021; 25(4): 287–290, doi: 10.1097/LGT.0000000000000625.
41. Di Donato V, Caruso G, Petrillo M, et al. Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis. Vaccines (Basel) 2021; 9(5): 410, doi: 10.3390/vaccines9050410.
42. Sand FL, Kjaer SK, Frederiksen K, et al. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status. Int J Cancer 2020; 147(3): 641–647, doi: 10.1002/ijc.32752.
43. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020.
44. European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction 2020. Stockholm: ECDC; 2020.
45. Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2019; 68: 698–702, doi: 10.15585/mmwr.mm6832a3.
46. Uchwaa nr 10 Rady Ministrów z dnia 4 lutego 2020 r. w sprawie przyjcia programu wieloletniego pn. Narodowa Strategia Onkologiczna na lata 2020–2030 (Dz.U. 2019, poz. 969) (in Polish).
47. Rekomendacja nr 128/2021 z dnia 25 listopada 2021 r. Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji w sprawie oceny leku Gardasil, szczepionka przeciw wirusowi brodawczaka ludzkiego [typy 6, 11, 16, 18] we wskazaniu: zapobieganie wystpienia u osób w wieku od 9 lat: zmian przednowotworowych narzdów pciowych (szyjki macicy, sromu i pochwy), zmian przednowotworowych odbytu, raka szyjki macicy oraz raka odbytu, zwizanych przyczynowo z zakaeniem pewnymi onkogennymi typami wirusa brodawczaka ludzkiego (HPV); brodawek narzdów pciowych (kykcin koczystych) zwizanych przyczynowo z zakaeniem okrelonymi typami wirusa brodawczaka ludzkiego (in Polish).
48. Rekomendacja nr 54/2021 z dnia 18 maja 2021 r. Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji w sprawie objcia refundacj leku Cervarix, szczepionka przeciw wirusowi brodawczaka ludzkiego [typy 16 i 18] we wskazaniu: profilaktyka zmian przednowotworowych narzdów pciowych i odbytu (szyjki macicy, sromu, pochwy i odbytu) oraz raka szyjki macicy i raka odbytu zwizanych przyczynowo z okrelonymi onkogennymi typami wirusa brodawczaka ludzkiego (HPV) u osób od ukoczenia 9. roku ycia (in Polish).
49. Nowakowski A, Arbyn M, Turkot MH, et al. A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. Eur J Cancer Prev 2020; 29(2): 157–164, doi: 10.1097/CEJ.0000000000000528.
50. Bidziski M, Debski R, Kedzia W, et al. Stanowisko zespou ekspertów Polskiego Towarzystwa Ginekologicznego na temat profilaktyki raka gruczoowego szyjki macicy. Ginekol Pol 2008; 79(10): 710–714.
51. Chybicka A, Jackowska T, Dobrzaska A, et al. Zalecenia grupy ekspertów dotyczce pierwotnej profilaktyki raka szyjki macicy u dziewczt i modych kobiet. Pediatr Pol 2010; 85(4): 360–370 (in Polish).
52. Agencja Oceny Technologii Medycznych i Taryfikacji, Wydzia Oceny Technologii Medycznych. Profilaktyka zakae wirusem brodawczaka ludzkiego (HPV) w ramach programów polityki zdrowotnej Warszawa. Raport w sprawie zalecanych technologii medycznych, dziaa przeprowadzanych w ramach programów polityki zdrowotnej oraz warunków realizacji tych programów polityki zdrowotnej – materiay dla Rady Przejrzystoci AOTMiT [cited 20.10.2021]. Available from URL: https://bipold.aotm.gov.pl/assets/files/ppz/2019/RPT/19.10.29_raport_zalec_techn_art_48aa_profilaktyka_hpv.pdf (in Polish).
53. Wydzia Zdrowia i Spraw Spoecznych Urzdu Miejskiego Wrocawia. Wrocawski program profilaktyki zakae wirusem brodawczaka ludzkiego [cited 20.10.2021]. Available from URL: https://hpv.um.wroc.pl/?p=561 (in Polish).
54. Ludwikowska KM, Szenborn L, Krzyanowska I, et al. Potrzeba, bezpieczestwo oraz realizacja szczepie przeciwko HPV – perspektywa wrocawska. Klin Pediatr 2018; 26(1): 26–30 (in Polish).
55. Ludwikowska KM, Biela M, Szenborn L. HPV vaccine acceptance and hesitancy – lessons learned during 8years of regional HPV prophylaxis program in Wroclaw, Poland. Eur J Cancer Prev 2020; 29(4): 346–349, doi: 10.1097/CEJ.0000000000000556.
56. Nguyen-Huu NH, Thilly N, Derrough T, et al. Human papillomavirus vaccination coverage, policies, and practical implementation across Europe. Vaccine 2020; 38(6): 1315–1331, doi: 10.1016/j.vaccine.2019.11.081.
57. Brown B, Gabra MI, Pellman H. Reasons for acceptance or refusal of Human Papillomavirus Vaccine in a California pediatric practice. Papillomavirus Res 2017; 3: 42–45, doi: 10.1016/j.pvr.2017.01.002.
58. Facciolŕ A, Visalli G, Orlando A, et al. Vaccine hesitancy: An overview on parents’ opinions about vaccination and possible reasons of vaccine refusal. J Public Health Res 2019; 8(1): 1436, doi: 10.4081/jphr.2019.1436.
Copyright: © 2022 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.